Endocannabinoids in the treatment of mood disorders: Evidence from animal models

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1623-1646

  Rodriguez Bambico, Francis ^a   Duranti, Andrea ^b   Tontini, Andrea ^b   Tarzia, Giorgio ^b   Gobbi, Gabriella ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

Antidepressant; Cannabinoid CB1 receptor; CB1 agonists and antagonists; Endocannabinoid; Fatty acid amide hydrolase (FAAH); Norepinephrine; Serotonin; URB597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 AG; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AM 411; AM 4113; AM 481; ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABICHROMENE; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABIS; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; LEVONANTRADOL; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; OLEAMIDE; RIMONABANT; SSR 411298; TETRAHYDROCANNABINOL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; CANNABINOID; SEROTONIN;

ANIMAL BEHAVIOR; ANXIETY DISORDER; BIPOLAR DISORDER; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CHRONIC STRESS; CLINICAL TRIAL; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FORCED SWIMMING TEST; GABAERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION STRESS; INTERNEURON; LOW DRUG DOSE; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; MOOD DISORDER; MOUSE TAIL SUSPENSION TEST; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE; PANIC; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RECEPTOR AFFINITY; RECEPTOR DENSITY; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOCIAL INTERACTION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CANNABINOIDS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; HUMANS; MICE; MICE, KNOCKOUT; NEUROGENESIS; RATS; RECEPTOR, CANNABINOID, CB1; SEROTONIN;

EID: 67650635375     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168029     Document Type: Review

References (243)

1. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatr Neurosci 2002; 27: 241-7.
2. Judd LL, Kunovac JL. Clinical characteristics and management of unipolar depressive disorders comorbid with neurological disorders. Neuropsychobiology 1998; 37: 84-7.
3. Zisook S, Ganadjian K, Moutier C, Prather R, Rao S. Sequenced treatment alternatives to relieve depression (STAR*D): Lessons learned. J Clin Psychiatry 2008; 69: 1184-5.
4. Bambico FR, Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: Possible antidepressant targets. Expert Opin Ther Targets 2008; 12: 1347-66.
5. Blier P, Demontigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-6.
6. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
7. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
8. Iversen L. The science of cannabis. Nord J Psychiatr 2004; 58: 87.
9. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 2007; 194: 505-15.
10. Musty R, Devo R. Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression. World Intellectual Organization. WO/2007/144628 2007.
11. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23.
12. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310 (5746): 329-32.
13. Di Marzo V, Bisogno T, De Petrocellis L. Anandamide: Some like it hot. Trends Pharmacol Sci 2001; 22: 346-9.
14. Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN, Hargreaves KM. Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem 2006; 281: 32879-90.
15. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA 2006; 103: 11393-8.
16. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27: 1-4.
17. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-704.
18. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1-4.
19. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16: 1395-8.
20. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004; 15: 299-304
21. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 2007; 104: 20588-93.
22. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci 2005; 77: 1685-98.
23. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of A Cannabinoid Receptor and Functional Expression of the Cloned Cdna. Nature 1990; 346(6284): 561-4.
24. Song ZH, Young WS, Brownstein JM, Bonner TI. Molecular-Cloning of A Novel Candidate G-Protein-Coupled Receptor from Rat-Brain. FEBS Lett 1994; 351: 375-9.
25. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostagland Leukot Essent Fatty Acids 2002; 66: 101-21.
26. Abadji V, Lucas-Lenard JM, Chin CN, Kendall DA. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of G(s). J Neurochem 1999; 72: 2032-8.
27. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a G(s) linkage to the CB1 receptor. J Neurosci 1997; 17: 5327-33.
28. Hampson RE, Mu JA, Deadwyler SA. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(S) proteins in cultured hippocampal neurons. J Neurophysiol 2000; 84: 2356-64.
29. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007; 5: 81-97.
30. Makara JK, Katona I, Nyiri G, Nemeth B, Ledent C, Watanabe M, et al. Involvement of nitric oxide in depolarization-induced suppression of inhibition in hippocampal pyramidal cells during activation of cholinergic receptors. J Neurosci 2007; 27: 10211-22.
31. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, Schroder, H et al. Membrane glycoprotein M6a interacts with the mu-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem 2007; 282: 22239-47.
32. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, Decosta BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
33. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
34. Bacci A, Huguenard JR, Prince DA. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 2004; 431 (7006): 312-6.
35. Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P, et al. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol 2007; 97: 2580-9
36. Wittmann G, Deli L, Kallo I, Hrabovszky E, Watanabe M, Liposits Z, et al. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol 2007; 503: 270-9.
37. Deli L, Wittmann G, Kallo I, Lechan RM, Watanabe M, Liposits Z, et al. Type 1 cannabinoid receptor (CB1)-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons. Endocrinology 2009; 150: 98-103.
38. Haring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007; 146: 1212-9.
39. Oropeza VC, Mackie K, Van Bockstaele EJ. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007; 1127: 36-44.
40. Lau T, Schloss P. The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons. Eur J Pharmacol 2008; 578: 137-41.
41. Ashton JC, Darlington CL, Smith PF. Co-distribution of the cannabinoid CB1 receptor and the 5-HT transporter in the rat amygdale. Eur J Pharmacol 2006; 537: 70-1.
42. Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000; 21: 1735-42.
43. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
44. Titishov N, Mechoulam R, Zimmerman AM. Stereospecific effects of (-)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl on the immune system of mice. Pharmacology 1989; 39: 337-49.
45. Luk T, Jin WZ, Zvonok A, Lu D, Lin XZ, Chavkin C, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004; 142: 495-500.
46. Johnson MR, Melvin LS, Althuis TH, Bindra JS, Harbert CA, Milne GM et al. Selective and Potent Analgetics Derived from Cannabinoids. J Clin Pharmacol 1981; 21: S271-82.
47. 3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol 1985; 109: 201-12.
48. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, et al. Conformationally restrained analogs of pravadoline - nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992; 35: 124-35.
49. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
50. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: Structure-activity relationships and potential therapeutic applications. Curr Top Med Chem 2008; 8: 205-30.
51. Gatley SJ, Gifford AN, Volkow ND, Lan RX, Makriyannis A. I-123-labeled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 1996; 307: 331-8.
52. Gifford AN, Tang YJ, Gatley SJ, Volkow ND, Lan RX, Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997; 238: 84-6.
53. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007; 91: 383-8.
54. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946-9.
55. Mechoulam R, Benshabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
56. Hanus LO. Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers 2007; 4: 1828-41.
57. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7: E625-54.
58. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptoralpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9.
59. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 (6690): 277-81.
60. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23: 7767-75.
61. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, de Fonseca FR, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003; 425 (6953): 90-3.
62. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 2007; 27: 3663-76.
63. Chevaleyre V, Castillo PE. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 2004; 43: 871-81.
64. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
65. Miczek KA. Delta-9-tetrahydrocannabinol - anti-aggressive effects in mice, rats, and squirrel-monkeys. Science 1978; 199 (4336): 1459-61
66. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 2003; 46: 2352-60.
67. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, et al. Cyclohexylcarbamic acid 3 '- or 4 '-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004; 47: 4998-5008.
68. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005; 313: 352-8.
69. Seierstad M, Breitenbrucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008; 51: 7327-43.
70. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435 (7045): 1108-12.
71. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277 (5329): 1094-7.
72. Egertova M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003; 119: 481-96.
73. Elphink MR, Egertova M. Cannabinoid signalling in the nervous system: Comparitve localization of CB1 receptors and fatty acid amide hydrolase in rat and mouse brain. Eur J Neurosci 2000; 12: 68.
74. Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proce R Soc London Series B-Biol Sci 1998; 265 (1410): 2081-5.
75. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-5.
76. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007; 62: 1103-10.
77. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006; 12: 21-38.
78. Russo R, LoVerme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007; 322: 236-42.
79. Moreira FA, Lutz B. The endocannabinoid system: Emotion, learning and addiction. Addict Biol 2008; 13: 196-212.
80. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008; 54: 141-50.
81. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A, et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008; 89: 64-75.
82. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008; 54: 129-40.
83. Lesch KP. Gene-environment interaction and the genetics of depression. J Psychiatr Neurosci 2004; 29: 174-84.
84. Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, et al. Measurement of brain regional alpha-[C-11]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004; 61: 556-63.
85. Leyton M, Ghadirian AM, Young SN, Palmour RM, Blier P, Helmers KF, et al. Depressive relapse following acute tryptophan depletion in patients with major depressive disorder. J Psychopharmacol 2000; 14: 284-7.
86. Mann JJ, Huang JY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical finding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729-38.
87. Blier P, De Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999; 21: S91-8.
88. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression Anxiety 2000; 12: 2-19.
89. MacQueen GM, Campbell S, McEwen B, Macdonald K, Young T. Course of illness, hippocampal function and volume in major depression. Biol Psychiatry 2003; 53: 31S.
90. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment. Biol Psychiatry 2004; 56: 101-12.
91. Posener JA, Wang L, Price JL, Gado MH, Province MA, Miller MI, et al. High-dimensional mapping of the hippocampus in depression. Am J Psychiatry 2003; 160: 83-9.
92. Mcewen BS, Conrad CD, Kuroda Y, Frankfurt M, Magarinos AM, McKittrick C. Prevention of stress-induced morphological and cognitive consequences. Eur Neuropsychopharmacol 1997; 7: 323-8.
93. Fossati P, Radtchenko A, Boyer P. Neuroplasticity: From MRI to depressive symptoms. Eur Neuropsychopharmacol 2004; 14: S503-10.
94. Johansen-Berg H, Gutman DA, Behrens TEJ, Matthews PM, Rushworth MFS, Katz E, et al. Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cerebral Cortex 2008; 18: 1374-83.
95. Dremencov E, Gur E, Lerer B, Newman ME. Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 729-39.
96. Kasckow JW, Baker D, Geracioti TD. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001; 22: 845-51.
97. Nemeroff CB, Vale WW. The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66: 5-13.
98. Leonard BE. Depression as a neurodegenerative disorder. Int J Neuropsychopharmacol 2006; 9: S32.
99. Cryan JF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nature Rev Drug Disc 2005; 4: 775-90.
100. McArthur R, Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav 2006; 84: 436-52.
101. Willner P. Animal models of depression: An overview. Pharmacol Ther 1990; 45: 425-55.
102. Porsolt RD, Bertin A, Jalfre M. "Behavioural despair" in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol 1978; 51: 291-4.
103. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-91.
104. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005; 15: 593-9.
105. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005; 115: 3104-16.
106. Adamczyk P, Golda A, McCreary AC, Filip M, Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008; 59: 217-28.
107. Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate Serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007; 27: 11700-11.
108. Hill MN, Karacabeyli ES, Gorzalka BB. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007; 32: 350-7.
109. Takahashi E, Katayama M, Niimi K, Itakura C. Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 2008; 589: 149-56.
110. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138: 544-53.
111. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003; 14: 573-82.
112. Egashira N, Matsuda T, Koushi E, Higashihara F, Mishima K, Chidori S, et al. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: Involvement of cannabinoid CB1 receptor and serotonergic system. Eur J Pharmacol 2008; 589: 117-21.
113. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001; 155: 315-22.
114. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity. Psychopharmacology 1988; 94: 147-60.
115. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. Br J Pharmacol 2007; 152: 583-93.
116. Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR. Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 2005; 22: 2387-91.
117. Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B, et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007; 25: 2445-56.
118. Rutkowska M, Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004; 61: 165-7.
119. Moreira F, Grieb M, Lutz B. Role for serotonin on the antidepressant-like effect induced by delta-9-tetrahydrocannabinol but not by rimonabant. Int Cannabinoid Res Soc Meeting 2008.
120. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005; 57: 261-7.
121. Niwatananun W, Myres MJ, Edwards E, Neuropsychopharmacology and molecular pharmacology of the cannabinoid system in the learned helpless model of depression. Pharmaceutical Sciences. Baltimore: University of Maryland 2000.
122. Macri S, Laviola G. Single episode of maternal deprivation and adult depressive profile in mice: Interaction with cannabinoid exposure during adolescence. Behav Brain Res 2004; 154: 231-8.
123. Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bachli H, et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenom J 2008; 8: 196-208.
124. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008; 33: 54-67.
125. Christensen R, Kristensen PK, Bartels EM, Blidda H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007; 370 (9600): 1706-13.
126. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 2002; 302: 73-9.
127. Leggett JD, Aspley S, Beckett SRG, D'Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004; 141: 253-62.
128. Hayase T. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: Effects of anxiolytic and cannabinoid drugs. BMC Neurosci 2007; 8: 76.
129. Bambico FR, Cassano T, Nguyen NT, Katz N, Macheda T, Morgese M, et al. Emotional behaviour and serotonergic neurotransmission in fatty acid amide hydrolase (FAAH) knockout mice. 37th Annual Meeting of the Society for Neuroscience 2007 November 3-7; Program 914.18, Poster II23.
130. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007; 192: 61-70.
131. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, et al. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 2005; 48: 1849-56.
132. Bachli H, Steiner MA, Habersetzer U, Wotjak CT. Increased water temperature renders single-housed C57BL/6J mice susceptible to antidepressant treatment in the forced swim test. Behav Brain Res 2008; 187: 67-71.
133. Kelliher P, Connor TJ, Harkin A, Sanchez C, Kelly JP, Leonard BE. Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. Physiol Behav 2000; 69: 531-9.
134. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999; 147: 162-7.
135. Moreira F, Grieb M, Lutz B. Role for serotonin on the antidepressant-like effect induced by delta-9-tetrahydrocannabinol but not by rimonabant. 18th Ann Sympo Int Cannabinoid Res Soc 2008; Abstract P70.
136. Morrish A, Hill M, Gorzalka B. Noradrenergic mediation of the antidepressant effect of long-term cannabinoid administration. 17th Ann Sympo Int Cannabinoid Res Soc 2007; Abstract 182.
137. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test - A new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367-70.
138. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625.
139. Musty R, Devo R. Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression. World Intellectual Organization 2007 WO/2007/144628.
140. Aso E, Renoir T, Ledent C, Hamon M, Maldonado R, Lanfumey L, et al. Lack of CB1 receptor alters serotonin system: An electrophysiological and in vivo microdialysis study. Eur Neuropsychopharmacol 2008; 18: S39.
141. Mato S, Aso E, Castro E, Martin M, Valverde O, Maldonado R, et al. CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 2007; 103: 2111-20.
142. Crowley JJ, Blendy JA, Lucki I. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 2005; 183: 257-64.
143. Mcguire PS, Seiden LS. The effects of tricyclic anti-depressants on performance under a differential-reinforcement-of-low-rates schedule in rats. J Pharmacol Exp Ther 1980; 214: 635-41.
144. O'Donnell JM, Marek GJ, Seiden LS. Antidepressant effects assessed using behavior maintained under a differentialreinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 2005; 29: 785-98.
145. Hiltunen AJ, Jarbe TUC, Kamkar MR, Archer T. Behavior in rats maintained by low differential reinforcement rate - Effects of delta-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combination. Neuropharmacology 1989; 28: 183-9.
146. Willmore CB, Kohler GD, Makriyannis A. Irt > t schedule controlled behavior in 'learned-helpless' rats: Effects from a cannabinoid agonist. Neuropharmacology 2006; 51: 90-101.
147. Bodnoff SR, Suranyicadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal-model of anxiety. Psychopharmacology 1988; 95: 298-302.
148. File SE, Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003; 463: 35-53.
149. Mitchell PJ, Fletcher A, Redfern PH. Is antidepressant efficacy revealed by drug-induced changes in rat behavior exhibited during social-interaction. Neurosci Biobehav Rev 1991; 15: 539-44.
150. Mitchell PJ, Redfern PH. Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635. Behav Pharmacol 1997; 8: 585-606.
151. Van Ree JM, Niesink RJ, Nir I. delta 1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters. Psychopharmacology (Berl) 1984; 84: 561-5.
152. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 2004; 77: 567-73.
153. Trezza V, Vanderschuren LJMJ. Cannabinoid and opioid modulation of social play behavior in adolescent rats: Differential behavioral mechanisms. Eur Neuropsychopharmacol 2008; 18: 519-30.
154. Trezza V, Vanderschuren LJMJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology 2008; 197: 217-27.
155. McGregor IS, Callaghan PD, Hunt GE. From ultrasocial to antisocial: A role for oxytocin in the acute reinforcing effects and longterm adverse consequences of drug use? Br J Pharmacol 2008; 154: 358-68.
156. Schneider M, Schomig E, Leweke FM. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 2008; 13: 345-57.
157. Trezza V, Vanderschuren L. Divergent Effects of Anandamide Transporter Inhibitors With Different Target Selectivity on Social Play Behavior in Adolescent Rats. J Pharmacol Exp Ther 2009; 328: 343-50.
158. Willner P. The chronic mild stress procedure as an animal model of depression: Valid, reasonably reliable, and useful. Psychopharmacology 1997; 134: 371-7.
159. Willner P. Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005; 52: 90-110.
160. Rademacher DJ, Hillard CJ. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 633-41.
161. Rademacher DJ, Meier SE, Shi LY, Ho WSV, Jarrahian A, Hillard CJ. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008; 54: 108-16.
162. Patel S, Hillard CJ. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: A novel mechanism for stress habituation. Eur J Neurosci 2008; 27: 2821-9.
163. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-15.
164. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379-87.
165. Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides 2005; 26: 1383-93.
166. Tao R, Auerbach SB. Regulation of serotonin release by GABA and excitatory amino acids. J Psychopharmacol 2000; 14: 100-113.
167. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66.
168. Post RM, Uhde TW, Rubinow DR, Huggins T. Differential time course of antidepressant effects after sleep-deprivation, ect, and carbamazepine - clinical and theoretical implications. Psychiatr Res 1987; 22: 11-9
169. Blier P, Demontigny C, Tardif D. Short-term lithium treatment enhances responsiveness of postsynaptic 5-Ht1A receptors without altering 5-Ht autoreceptor sensitivity - an electrophysiological study in the rat-brain. Synapse 1987; 1: 225-32.
170. Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998; 18: 10150-6.
171. Linner L, Wiker C, Arborelius L, Schalling M, Svensson TH. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J Neural Transm 2004; 111: 127-39.
172. Lucas G, Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 2002; 16: 817-22.
173. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. Serotonin(4) (5-HT4) receptor Agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55: 712-25.
174. Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L, et al. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 2007; 17: 328-38.
175. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005; 97: 317-36.
176. Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006; 318: 890-8
177. Santarelli L, Gobbi G, Debs PC, Sibille EL, Blier P, Hen R, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001; 98: 1912-7.
178. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006; 9: 1134-41.
179. Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in-vivo. J Pharmacol Exp Ther 1995; 274: 866-76.
180. Cremers TIFH, Spoelstra EN, de Boer P, Bosker FJ, Mork A, den Boer JA, et al. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur J Pharmacol 2000; 397: 351-7.
181. Cremers TIFH, de Boer P, Liao Y, Bosker FJ, den Boer JA, Westerink BHC, et al. Augmentation with a 5-HT1A but not a 5-HT1B receptor antagonist critically depends on the dose of citalopram. Eur J Pharmacol 2000; 397: 63-74.
182. Beique JC, De Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. Neuropharmacology 2000; 39: 1813-22.
183. Assie MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A. Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: A microdialysis study in the rat. Br J Pharmacol 2006; 149: 170-8.
184. Miguez JM, Paz-Valinas L, Miguez I, Aldegunde M. Somatodendritic action of pindolol to attenuate the paroxetine-induced decrease in serotonin release from the rat ventral hippocampus: A microdialysis study. Naunyn-Schmiedebergs Arch Pharmacol 2002; 365: 378-87.
185. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Effects of venlafaxine on extracellular 5-HT, doparnine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo. Life Sci 2003; 73: 2433-42
186. Hajos-Korcsok E, McTavish SFB, Sharp T. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: Microdialysis studies using paroxetine. Eur J Pharmacol 2000; 407: 101-7.
187. Zis AP, Nomikos GG, Brown EE, Damsma G, Fibiger HC. Neurochemical effects of electrically and chemically-induced seizures - an in vivo microdialysis study in the rat hippocampus. Neuropsychopharmacology 1992; 7: 189-5.
188. Juckel G, Mendlin A, Jacobs BL. Electrical stimulation of rat medial prefrontal cortex enhances forebrain serotonin output: Implications for electroconvulsive therapy and transcranial magnetic stimulation in depression. Neuropsychopharmacology 1999; 21: 391-8.
189. Bequet F, Gomez-Merino D, Berthelot M, Guezennec CY. Evidence that brain glucose availability influences exercise-enhanced extracellular 5-HT level in hippocampus: A microdialysis study in exercising rats. Acta Physiol Scand 2002; 176: 65-9.
190. Kang M, Pyun KH, Jang CG, Kim H, Bae H, Shim I. Nelumbinis Semen reverses a decrease in hippocampal 5-HT release induced by chronic mild stress in rats. J Pharm Pharmacol 2005; 57: 651-6.
191. van der Stelt HM, Breuer ME, Olivier B, Westenberg HGM. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: An in vivo microdialysis study. Biol Psychiatry 2005; 57: 1061-7
192. van der Stelt HM, Broersen LM, Olivier B, Westenberg HGM. Effects of dietary tryptophan variations on extracellular serotonin in the dorsal hippocampus of rats. Psychopharmacology 2004; 172: 137-44.
193. Besson A, Haddjeri N, Blier P, de Montigny C. Effects of the coadministration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000; 10: 177-88.
194. Nibuya M, Morinobu S, Duman RS. Regulation of Bdnf and Trkb messenger-RNA in rat-brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
195. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
196. Bambico F, Katz N, Debonnel G, Gobbi G. Modulation of serotonergic neuronal firing activity by cannabinoid CB1 agonists. Acta Pharmacol Sinica 2006; 27: 80.
197. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
198. Aso E, Ozaita A, Valdizan EM, Ledent C, Pazos A, Maldonado R, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008; 105: 565-72.
199. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379-87.
200. Welch BL, Welch AS, Messiha FS, Berger HJ. Rapid depletion of adrenal epinephrine and elevation of telencephalic serotonin by (-)-Trans-Delta-9-tetrahydrocannabinol in mice. Res Commun Chem Pathol Pharmacol 1971; 2: 382-91.
201. Segawa T, Takeuchi S, Nakano M. Mechanism for Increase of Brain 5-Hydroxytryptamine and 5-Hydroxyindoleacetic Acid Following Delta-9-Tetrahydrocannabinol Administration to Rats. Jap J Pharmacol 1976; 26: 377-9.
202. Sagredo O, Ramos JA, Fernandez-Ruiz J, Rodriguez ML, de Miguel R. Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 313-7.
203. Thiemann G, Di Marzo V, Molleman A, Hasenohrl RU. The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol Biochem Behav 2008; 89: 384-91.
204. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta(9)-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007; 555: 156-63.
205. Egashira N, Matsuda T, Koushi E, Mishima K, Iwasaki K, Shoyama Y, et al. Involvement of 5-hydroxytryptamine(1A) receptors in Delta(9)-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Eur J Pharmacol 2006; 550: 117-22.
206. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 2004; 15: 21-7.
207. Hill MN, Sun JC, Tse MTL, Gorzalka BB. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 2006; 9: 277-86.
208. Bambico FR, Hattan PR, Katz N, Labonte B, Duranti A, Tontini A, et al. Differences between direct cannabinoid agonists and FAAH inhibitors on antidepressant-like behavior and on modulation of serotonin activity. 38th Ann Meeting Soc Neurosci 2008; Program 560.7, Poster EE23.
209. Frazer A. Norepinephrine involvement in antidepressant action. J Clin Psychiatry 2000; 61: 25-30.
210. Guiard BP, El Mansari M, Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 2008; 74: 1463-75.
211. Dahlström A, Fuxe K. Evidence for existence of monoamine neurons in central nervous system. 2 Experimentally induced changes in intraneuronal amine levels of bulbospinal neuron systems. 4 Distribution of monoamine nerve terminals in central nervous system. Acta Physiol Scand 1965; S64: 7.
212. Szabo ST, Blier P. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 2001; 50: 644-6.
213. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatr Neurosci 2001; 26: S3-10.
214. Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affecti Disord 2008; 110: 1-15.
215. Mendiguren A, Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 2006; 534: 83-8.
216. Mendiguren A, Pineda J. Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neurosci Lett 2004; 363: 1-5.
217. Mendiguren A, Pineda J. CB1 cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Neuropharmacology 2007; 52: 617-25.
218. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007; 32: 1032-41
219. Jentsch JD, Andrusiak E, Tran A, Bowers MB, Roth RH. Delta(9)-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: Blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997; 16: 426-32.
220. Oropeza VC, Page ME, Van Bockstaele EJ. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005; 1046: 45-54.
221. Page ME, Oropeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 2007; 86: 162-8.
222. Moranta D, Esteban S, Garcia-Sevilla JA. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369: 516-24.
223. Schlicker E, Timm J, Zentner J, Gothert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedebergs Arch Pharmacol 1997; 356: 583-9.
224. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 2001; 426: R3-4.
225. Bolwig TG, Madsen TM. Electroconvulsive therapy in melancholia: The role of hippocampal neurogenesis. Acta Psychiatr Scand 2007; 115: 130-5.
226. Lee HJ, Kim JW, Yim SV, Kim MJ, Kim SA, Kim YJ, et al. Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001; 6: 725-8.
227. Airan RD, Meltzer LA, Roy M, Gong YQ, Chen H, Deisseroth K. High-speed Imaging reveals neurophysiological links to behavior in an animal model of depression. Science 2007; 317 (5839): 819-23.
228. Chaperon F, Thiebot MH. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13: 243-81.
229. Liapi A, Wood JN. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 2005; 22: 825-34.
230. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155-63.
231. Hajos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002; 43: 503-10.
232. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
233. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1-and non-CB1-mediated actions. Neuropharmacology 2004; 46: 115-25.
234. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006; 316: 969-82.
235. Hajos N, Freund TF. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Physics Lipids 2002; 121: 73-82.
236. Haj-Dahmane S, Shen RY. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci 2005; 25: 896-905.
237. Moreau de Tours JJ. Du haschisch et de l'alienation mentale. Moreau JJ Ed. Paris, Librairie de Masson 1845.
238. Mitchell PB, Morris M. Depression and anxiety with rimonabant. Lancet 2007; 370 (9600): 1671-2.
239. Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry 1997; 41: 196-200.
240. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68: 1056-61.
241. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008; 14(23): 2347-61.
242. Viso A, Cisneros JA, Ortega-Gutierrez S. The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr Top Med Chem 2008; 8(3): 231-46.
243. Yang H, Chen C. Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008; 14(14): 1443-51.